drugset / Trial / NCT00003929

Chemotherapy, Filgrastim, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma

NCT00003929

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Combining chemotherapy with radiation therapy may kill more cancer cells. Colony-stimulating factors such as filgrastim allow doctors to give higher doses of chemotherapy drugs to kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of lomustine, procarbazine, filgrastim, and radiation therapy in treating patients who have primary central nervous system lymphoma.

Timeline

Start
1998-06
Primary completion
2000-03
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Lomustine Small molecule Oral
Subject filgrastim Protein / enzyme biologic Subcutaneous
Subject procarbazine Small molecule Oral

Indications